The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).
 
Frank A. Sinicrope
Stock and Other Ownership Interests - illumina
Honoraria - American Society of Clinical Oncology; Imedex
Consulting or Advisory Role - EMD Serono; Roche; Roche/Genentech; Ventana Medical Systems
Travel, Accommodations, Expenses - ventana medical systems
 
Qian Shi
No Relationships to Disclose
 
Fabienne Hermitte
No Relationships to Disclose
 
Erica N Heying
No Relationships to Disclose
 
Al Bowen Benson
Consulting or Advisory Role - Advanced Accelerator Applications; Alchemia; Astellas Pharma; Bayer; Bayer/Onyx; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; Guardant Health; Guerbet; Helsinn Healthcare; Infinity Pharmaceuticals; IntegraGen; Lexicon; Lilly; Lilly/ImClone; Merck Serono; Novartis; Opsona Therapeutics; Pharmacyclics; Precision Therapeutics; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; TRM Oncology; Vicus Therapeutics
Research Funding - advanced accelerator applications (Inst); Alchemia (Inst); Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer/Onyx (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Boston Biomedical; Dava Oncology; Genentech/Roche; Gilead Sciences; Guardant Health; guerbet; Helsinn Healthcare; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology
 
Sharlene Gill
Honoraria - Celgene; Lilly
Consulting or Advisory Role - Celgene; Lilly; Shire; Taiho Pharmaceutical
Research Funding - Celgene
 
Richard Goldberg
No Relationships to Disclose
 
Morton S. Kahlenberg
No Relationships to Disclose
 
Suresh Nair
No Relationships to Disclose
 
Anthony Frank Shields
Employment - Benchling (I)
Stock and Other Ownership Interests - Benchling (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Endocyte; GE Healthcare; Merck; Merrimack; Personal Genome Diagnostics; Siemens Healthcare Diagnostics; Taiho Pharmaceutical
Speakers' Bureau - GE Healthcare
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eisai; H3 Biomedicine; Inovio Pharmaceuticals; Karyopharm Therapeutics; Merrimack; Novartis; OncoMed; Plexxikon; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Caris Life Sciences; Endocyte; GE Healthcare; Merrimack
 
Daniel J. Sargent
Consulting or Advisory Role - Abbvie; Acerta Pharma; ARIAD; Astellas Pharma; AstraZeneca/MedImmune; Biothera; Celldex; Exelixis; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; Merrimack; Nektar; Novartis; Pharmacyclics; Pique; Spiration; Xbiotech
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene
 
Jerome Galon
No Relationships to Disclose
 
Steven R. Alberts
No Relationships to Disclose